The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Chromadax     (1S,4S,7Z,10R,16E,21R)-7- ethylidene-4,21...

Synonyms: Istodax, Romidepsin, romidepsina, romidepsine, Depsipeptide, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of FK 228


High impact information on FK 228


Biological context of FK 228


Anatomical context of FK 228


Associations of FK 228 with other chemical compounds


Gene context of FK 228


Analytical, diagnostic and therapeutic context of FK 228


  1. Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. Kitazono, M., Rao, V.K., Robey, R., Aikou, T., Bates, S., Fojo, T., Goldsmith, M.E. Blood (2002) [Pubmed]
  2. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Byrd, J.C., Shinn, C., Ravi, R., Willis, C.R., Waselenko, J.K., Flinn, I.W., Dawson, N.A., Grever, M.R. Blood (1999) [Pubmed]
  3. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Watanabe, K., Okamoto, K., Yonehara, S. Cell Death Differ. (2005) [Pubmed]
  4. Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Pong, R.C., Lai, Y.J., Chen, H., Okegawa, T., Frenkel, E., Sagalowsky, A., Hsieh, J.T. Cancer Res. (2003) [Pubmed]
  5. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Imai, T., Adachi, S., Nishijo, K., Ohgushi, M., Okada, M., Yasumi, T., Watanabe, K., Nishikomori, R., Nakayama, T., Yonehara, S., Toguchida, J., Nakahata, T. Oncogene (2003) [Pubmed]
  6. Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer. Fan, J., Stanfield, J., Guo, Y., Karam, J.A., Frenkel, E., Sun, X., Hsieh, J.T. Clin. Cancer Res. (2008) [Pubmed]
  7. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. Yu, X., Guo, Z.S., Marcu, M.G., Neckers, L., Nguyen, D.M., Chen, G.A., Schrump, D.S. J. Natl. Cancer Inst. (2002) [Pubmed]
  8. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Aron, J.L., Parthun, M.R., Marcucci, G., Kitada, S., Mone, A.P., Davis, M.E., Shen, T., Murphy, T., Wickham, J., Kanakry, C., Lucas, D.M., Reed, J.C., Grever, M.R., Byrd, J.C. Blood (2003) [Pubmed]
  9. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Piekarz, R.L., Robey, R., Sandor, V., Bakke, S., Wilson, W.H., Dahmoush, L., Kingma, D.M., Turner, M.L., Altemus, R., Bates, S.E. Blood (2001) [Pubmed]
  10. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Kitazono, M., Goldsmith, M.E., Aikou, T., Bates, S., Fojo, T. Cancer Res. (2001) [Pubmed]
  11. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Nakajima, H., Kim, Y.B., Terano, H., Yoshida, M., Horinouchi, S. Exp. Cell Res. (1998) [Pubmed]
  12. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Sandor, V., Bakke, S., Robey, R.W., Kang, M.H., Blagosklonny, M.V., Bender, J., Brooks, R., Piekarz, R.L., Tucker, E., Figg, W.D., Chan, K.K., Goldspiel, B., Fojo, A.T., Balcerzak, S.P., Bates, S.E. Clin. Cancer Res. (2002) [Pubmed]
  13. Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. Yamano, T., Ura, K., Morishita, R., Nakajima, H., Monden, M., Kaneda, Y. Mol. Ther. (2000) [Pubmed]
  14. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. Nakamura, T., Kukita, T., Shobuike, T., Nagata, K., Wu, Z., Ogawa, K., Hotokebuchi, T., Kohashi, O., Kukita, A. J. Immunol. (2005) [Pubmed]
  15. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Wang, R., Brunner, T., Zhang, L., Shi, Y. Oncogene (1998) [Pubmed]
  16. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Blanchard, F., Kinzie, E., Wang, Y., Duplomb, L., Godard, A., Held, W.A., Asch, B.B., Baumann, H. Oncogene (2002) [Pubmed]
  17. Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. Murakami, J., Asaumi, J., Kawai, N., Tsujigiwa, H., Yanagi, Y., Nagatsuka, H., Inoue, T., Kokeguchi, S., Kawasaki, S., Kuroda, M., Tanaka, N., Matsubara, N., Kishi, K. Cancer Chemother. Pharmacol. (2005) [Pubmed]
  18. A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells. Okada, T., Uchibori, R., Iwata-Okada, M., Takahashi, M., Nomoto, T., Nonaka-Sarukawa, M., Ito, T., Liu, Y., Mizukami, H., Kume, A., Kobayashi, E., Ozawa, K. Mol. Ther. (2006) [Pubmed]
  19. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. Tsurutani, J., Soda, H., Oka, M., Suenaga, M., Doi, S., Nakamura, Y., Nakatomi, K., Shiozawa, K., Amada, Y.Y., Kamihira, S., Kohno, S. Int. J. Cancer (2003) [Pubmed]
  20. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Sandor, V., Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M.V., Bates, S.E. Br. J. Cancer (2000) [Pubmed]
  21. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. Kim, Y.B., Ki, S.W., Yoshida, M., Horinouchi, S. J. Antibiot. (2000) [Pubmed]
  22. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Robey, R.W., Zhan, Z., Piekarz, R.L., Kayastha, G.L., Fojo, T., Bates, S.E. Clin. Cancer Res. (2006) [Pubmed]
  23. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Watanabe, T., Hioki, M., Fujiwara, T., Nishizaki, M., Kagawa, S., Taki, M., Kishimoto, H., Endo, Y., Urata, Y., Tanaka, N., Fujiwara, T. Exp. Cell Res. (2006) [Pubmed]
WikiGenes - Universities